Ambient heat exposure and kidney function in patients with chronic kidney disease: a post-hoc analysis of the DAPA-CKD trial

被引:4
|
作者
Zhang, Zhiyan [1 ]
Heerspink, Hiddo J. L. [4 ]
Chertow, Glenn M. [6 ,7 ]
Correa-Rotter, Ricardo [8 ]
Gasparrini, Antonio [2 ]
Jongs, Niels [4 ]
Langkilde, Anna Maria [9 ]
McMurray, John J., V [5 ,10 ]
Mistry, Malcolm N. [2 ,11 ]
Rossing, Peter [12 ]
Toto, Robert [13 ]
Vart, Priya [4 ]
Nitsch, Dorothea [3 ]
Wheeler, David C. [14 ]
Caplin, Ben [14 ]
机构
[1] London Sch Hyg & Trop Med, Dept Med Stat, London, England
[2] London Sch Hyg & Trop Med, Dept Publ Hlth Environm & Soc, Environm & Hlth Modelling Lab, London, England
[3] London Sch Hyg & Trop Med, Dept Noncommunicable Dis Epidemiol, London, England
[4] Univ Groningen, Dept Clin Pharm & Pharmacol, Groningen, Netherlands
[5] George Inst Global Hlth, Sydney, NSW, Australia
[6] Stanford Univ, Sch Med, Dept Epidemiol & Populat Hlth, Dept Med, Stanford, CA USA
[7] Stanford Univ, Dept Hlth Policy, Sch Med, Stanford, CA USA
[8] Inst Nacl Ciencias Med & Nutr Salvador Zubiran, Mexico City, Mexico
[9] AstraZeneca, Biopharmaceut R&D, Gothenburg, Sweden
[10] Univ Glasgow, Inst Cardiovasc & Med Sci, Glasgow, Scotland
[11] Ca Foscari Univ Venice, Dept Econ, Venice, Italy
[12] Univ Copenhagen, Dept Clin Med, Copenhagen, Denmark
[13] UT Southwestern Med Ctr, Dept Internal Med, Dallas, TX USA
[14] UCL, Dept Renal Med, London NW3 2PF, England
来源
LANCET PLANETARY HEALTH | 2024年 / 8卷 / 04期
基金
英国医学研究理事会;
关键词
CLIMATE-CHANGE; TEMPERATURE; STRESS; COMMUNITIES;
D O I
10.1016/S2542-5196(24)00026-3
中图分类号
X [环境科学、安全科学];
学科分类号
08 ; 0830 ;
摘要
Background Higher temperatures are associated with higher rates of hospital admissions for nephrolithiasis and acute kidney injury. Occupational heat stress is also a risk factor for kidney dysfunction in resource-poor settings. It is unclear whether ambient heat exposure is associated with loss of kidney function in patients with established chronic kidney disease. We assessed the association between heat index and change in estimated glomerular filtration rate (eGFR) in participants from the DAPA-CKD trial in a post-hoc analysis. Methods DAPA-CKD was a randomised controlled trial of oral dapagliflozin 10 mg once daily or placebo that enrolled participants aged 18 years or older, with or without type 2 diabetes, with a urinary albumin-to-creatinine ratio of 200-5000 mg/g, and an eGFR of 25-75 mL/min per 1<middle dot>73 m(2). In this post-hoc analysis, we explored the association between time-varying daily centre-level heat index (ERA5 dataset) and individual-level change in eGFR in trial participants using linear mixed effect models and case-time series. The DAPA-CKD trial is registered with ClinicalTrials.gov, NCT03036150. Findings Climate and eGFR data were available for 4017 (93<middle dot>3%) of 4304 participants in 21 countries (mean age: 61<middle dot>9 years; mean eGFR: 43<middle dot>3 mL per 1<middle dot>73 m(2); median 28 months follow-up). Across centres, a heat index of more than 30 degrees C occurred on a median of 0<middle dot>6% of days. In adjusted linear mixed effect models, within each 120-day window, each 30 days' heat index of more than 30 degrees C was associated with a -0<middle dot>6% (95% CI -0<middle dot>9% to -0<middle dot>3%) change in eGFR. Similar estimates were obtained using case-time series. Additional analyses over longer time-windows showed associations consistent with haemodynamic or seasonal variability, or both, but overall estimates corresponded to an additional 3<middle dot>7 mL per 1<middle dot>73 m(2) (95% CI 0<middle dot>1 to 7<middle dot>0) loss of eGFR per year in a patient with an eGFR of 45 mL per 1<middle dot>73 m(2) located in a very hot versus a temperate environment. Interpretation Higher ambient heat exposure is associated with more rapid eGFR decline in those with established chronic kidney disease. Efforts to mitigate heat exposure should be tested as part of strategies to attenuate chronic kidney disease progression.
引用
收藏
页码:e225 / e233
页数:9
相关论文
共 50 条
  • [1] AMBIENT HEAT EXPOSURE AND ESTIMATED GLOMERULAR FILTRATION RATE TRAJECTORY: A POST-HOC ANALYSIS OF THE DAPA-CKD TRIAL
    Zhang, Zhiyan
    Ileerspink, Hiddo Lambers
    Chertow, Glenn
    Correa-Rotter, Ricardo
    Gasparrini, Antonio
    Jong, Niels
    Langkilde, Anna Maria
    Mistry, Malcolm
    Mcmurray, John
    Rossing, Peter
    Toto, Robert
    Vart, Priya
    Misch, Dorothea
    Wheeler, David C.
    Ben Caplin
    NEPHROLOGY DIALYSIS TRANSPLANTATION, 2023, 38 : I472 - I472
  • [2] Effects of Dapagliflozin on Hospitalizations in Patients With Chronic Kidney Disease: A Post Hoc Analysis of DAPA-CKD
    Schechter, Meir
    Jongs, Niels
    Chertow, Glenn M.
    Mosenzon, Ofri
    McMurray, John J., V
    Correa-Rotter, Ricardo
    Rossing, Peter
    Langkilde, Anna Maria
    Sjostrom, C. David
    Toto, Robert D.
    Wheeler, David C.
    Heerspink, Hiddo J. L.
    ANNALS OF INTERNAL MEDICINE, 2023, 176 (01) : 59 - +
  • [3] Dapagliflozin Effect on Hospital Admissions in Patients With CKD: A Post Hoc Analysis of the DAPA-CKD Trial
    Schechter, Meir
    Jongs, Niels
    Chertow, Glenn
    Mosenzon, Ofri
    McMurray, John
    Correa-Rotter, Ricardo
    Rossing, Peter
    Langkilde, Anna Maria
    Sjostrom, David
    Toto, Robert D.
    Wheeler, David C.
    Heerspink, Hiddo J. L.
    JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2022, 33 (11): : 25 - 25
  • [4] Dapagliflozin in chronic kidney disease: cost-effectiveness beyond the DAPA-CKD trial
    McEwan, Phil
    Davis, Jason A.
    Gabb, Peter D.
    Wheeler, David C.
    Rossing, Peter
    Chertow, Glenn M.
    Correa-Rotter, Ricardo
    Tamura, Kouichi
    Barone, Salvatore
    Sanchez, Juan Jose Garcia
    CLINICAL KIDNEY JOURNAL, 2024, 17 (02)
  • [5] The Effect of Dapagliflozin on Rate of Kidney Function Decline in Patients with CKD: A Prespecified Analysis from the DAPA-CKD Trial
    Heerspink, Hiddo J. L.
    Jongs, Niels
    Chertow, Glenn M.
    Langkilde, Anna Maria
    McMurray, John
    Correa-Rotter, Ricardo
    Rossing, Peter
    Sjostrom, David
    Stefansson, Bergur V.
    Toto, Robert D.
    Wheeler, David C.
    Greene, Tom
    JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2021, 32 (10): : 35 - 36
  • [6] Dapagliflozin And Prevention of Adverse outcomes in Chronic Kidney Disease (DAPA-CKD)
    McMurray, John J. V.
    Wheeler, David C.
    Stefansson, Bergur V.
    Correa-Rotter, Ricardo
    Chertow, Glenn M.
    Greene, Tom
    Hou, Fan Fan
    Lindberg, Magnus B.
    Rossing, Peter
    Sjostrom, C. David
    Toto, Robert D.
    Langkilde, Ann Maria
    Heerspink, Hiddo J. L.
    JOURNAL OF CARDIAC FAILURE, 2020, 26 (12) : 1111 - 1111
  • [7] Dapagliflozin and Prevention of Adverse Outcomes in Chronic Kidney Disease (DAPA-CKD)
    McMurray, John J.
    Wheeler, David C.
    Stefansson, Bergur V.
    Rotter, Ricardo Correa
    Chertow, Glenn M.
    Greene, Tom
    Hou, Fan Fan
    Lindberg, Magnus B.
    Rossing, Peter
    Sjostrom, David
    Toto, Robert D.
    Langkilde, Anna Maria
    Heerspink, Hiddo J. Lambers
    CIRCULATION, 2020, 142 (24) : E482 - E483
  • [8] Effect of dapagliflozin on kidney and cardiovascular outcomes by baseline KDIGO risk categories: a post hoc analysis of the DAPA-CKD trial
    Waijer, Simke W.
    Vart, Priya
    Cherney, David Z., I
    Chertow, Glenn M.
    Jongs, Niels
    Langkilde, Anna Maria
    Mann, Johannes F. E.
    Mosenzon, Ofri
    McMurray, John J., V
    Rossing, Peter
    Correa-Rotter, Ricardo
    Stefansson, Bergur, V
    Toto, Robert D.
    Wheeler, David C.
    Heerspink, Hiddo J. L.
    DIABETOLOGIA, 2022, 65 (07) : 1085 - 1097
  • [9] Effect of dapagliflozin on the rate of decline in kidney function in patients with chronic kidney disease with and without type 2 diabetes: a prespecified analysis from the DAPA-CKD trial
    Heerspink, Hiddo J. L.
    Jongs, Niels
    Chertow, Glenn M.
    Langkilde, Anna Maria
    McMurray, John J., V
    Correa-Rotter, Ricardo
    Rossing, Peter
    Sjostrom, C. David
    Stefansson, Bergur, V
    Toto, Robert D.
    Wheeler, David C.
    Greene, Tom
    LANCET DIABETES & ENDOCRINOLOGY, 2021, 9 (11): : 743 - 754
  • [10] Effect of dapagliflozin on kidney and cardiovascular outcomes by baseline KDIGO risk categories: a post hoc analysis of the DAPA-CKD trial
    Simke W. Waijer
    Priya Vart
    David Z. I. Cherney
    Glenn M. Chertow
    Niels Jongs
    Anna Maria Langkilde
    Johannes F. E. Mann
    Ofri Mosenzon
    John J. V. McMurray
    Peter Rossing
    Ricardo Correa-Rotter
    Bergur V. Stefansson
    Robert D. Toto
    David C. Wheeler
    Hiddo J. L. Heerspink
    Diabetologia, 2022, 65 : 1085 - 1097